Description: IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
Home Page: www.iobiotech.com
IOBT Technical Analysis
Ole Maaløes Vej 3
Copenhagen,
2200
Denmark
Phone:
45 70 70 29 80
Officers
| Name | Title |
|---|---|
| Dr. Mai-Britt Zocca Ph.D. | Founder, Pres, CEO, Principal Financial Officer & Director |
| Dr. Muhammad Al-Hajj Ph.D. | Chief Scientific Officer |
| Dr. Eva Ehrnrooth M.D., Ph.D. | Chief Medical Officer |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder & Clinical Advisor |
| Prof. Mads Hald Andersen Ph.D. | Founder & Scientific Advisor |
| Anders Ljungqvist | Founder |
| Prof. Per Thor Straten | Founder |
| Ms. Amy B. Sullivan | Chief Financial Officer |
| Mr. Brian Burkavage | VP of Fin. & Chief Accounting Officer |
| Mr. Mikkel Dybkjær | VP of Corp. Fin. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5238 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-11-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 32 |